-
Mashup Score: 0
Some U.S. patients taking the two highest doses of Novo Nordisk’s Wegovy weight-loss drug are facing difficulty filling their prescriptions, eight doctors around the country told Reuters this week, suggesting a new supply challenge for the popular medicine.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0UnitedHealth's lower-than-feared costs lift profit, shares - 2 year(s) ago
UnitedHealth Group’s quarterly profit beat Wall Street estimates on Friday as a smaller-than-expected jump in medical costs allayed fears that a resumption in long-delayed surgical procedures would hit profit growth, sending its shares up 8%.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
UnitedHealth Group's quarterly profit beat Wall Street estimates on Friday as a smaller-than-expected jump in medical costs allayed fears that a resumption in long-delayed surgical procedures would hit profit growth, sending its shares up 8%. https://t.co/LMW2q9TDrq
-
-
Mashup Score: 0
Novo Nordisk on Friday urged doctors in Germany to limit prescriptions of its popular Wegovy weight-loss drug to patients with medical needs, citing limited supplies as the company prepares to launch in Europe’s largest pharmaceutical market.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
Novo Nordisk on Friday urged doctors in Germany to limit prescriptions of its popular Wegovy weight-loss drug to patients with medical needs, citing limited supplies as the company prepares to launch in Europe's largest pharmaceutical market. https://t.co/X1YTMXEfnP
-
-
Mashup Score: 6
Aspartame, the artificial sweetener used in products from Coca-Cola’s diet sodas to Mars’ Extra chewing gum, is the latest substance to be declared a possible carcinogen by the International Agency for Research on Cancer (IARC).
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
Aspartame, the artificial sweetener used in products from Coca-Cola's diet sodas to Mars' Extra chewing gum, is the latest substance to be declared a possible carcinogen by the International Agency for Research on Cancer (IARC). https://t.co/bsOgOCmMVf
-
-
Mashup Score: 1
The sweetener aspartame is a “possible carcinogen” but it remains safe to consume at already-agreed levels, two groups linked to the World Health Organization (WHO) declared on Friday.
Source: ReutersCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our Dr. Therese Bevers shares her insights on @WHO’s classification of aspartame as a potential carcinogen: “The possibility of weight gain and obesity is a much bigger problem and bigger risk factor than aspartame could ever be.” https://t.co/kyNixjfqt2 #EndCancer https://t.co/Y3Or1gCczx
-
-
Mashup Score: 9Strong U.S. demand eases pressure on Novo to show weight-loss drug's health benefits - 2 year(s) ago
Soaring U.S. demand for Novo Nordisk’s weight-loss drug has reduced the pressure from investors on the company to deliver strong results in its trial to test whether the drug also has medical benefits, eight investors and analysts say.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
Soaring U.S. demand for Novo Nordisk's weight-loss drug has reduced the pressure from investors on the company to deliver strong results in its trial to test whether the drug also has medical benefits, eight investors and analysts say. https://t.co/lfpUnxvAGp
-
-
Mashup Score: 2Fresenius Medical shareholders approve change in legal form - 2 year(s) ago
Fresenius Medical Care said on Friday that shareholders voted with a 99.88% majority in favour of a change that will simplify its governance and make parent Fresenius SE a regular minority shareholder.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
Fresenius Medical Care said on Friday that shareholders voted with a 99.88% majority in favour of a change that will simplify its governance and make parent Fresenius SE a regular minority shareholder. https://t.co/pr1YvFuSW3
-
-
Mashup Score: 1UnitedHealth's lower-than-feared costs lift profit, shares - 2 year(s) ago
UnitedHealth Group’s quarterly profit beat Wall Street estimates on Friday as a smaller-than-expected jump in medical costs allayed fears that a resumption in long-delayed surgical procedures would hit profit growth, sending its shares up 5%.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
UnitedHealth Group's quarterly profit beat Wall Street estimates on Friday as a smaller-than-expected jump in medical costs allayed fears that a resumption in long-delayed surgical procedures would hit profit growth, sending its shares up 5%. https://t.co/y9clMPP8ZJ
-
-
Mashup Score: 1Novo Nordisk prices Wegovy weight-loss drug for German launch - 2 year(s) ago
Novo Nordisk said on Friday its popular weight-loss drug Wegovy will cost 301.91 euros ($338.35) for four weeks of treatment at the highest dose in Germany, as it prepares to launch in Europe’s largest pharmaceutical market at the end of the month.
Source: ReutersCategories: General Medicine News, Latest HeadlinesTweet-
Novo Nordisk said on Friday its popular weight-loss drug Wegovy will cost 301.91 euros ($338.35) for four weeks of treatment at the highest dose in Germany, as it prepares to launch in Europe's largest pharmaceutical market at the end of the month. https://t.co/SLM7vPc1lD
-
-
Mashup Score: 0
Twenty-seven global investors managing $2.1 trillion are collaborating to help companies reduce the potential negative impacts of technology on the mental health of their customers, the group’s leaders said on Tuesday.
Source: ReutersCategories: Healthcare Professionals, Latest HeadlinesTweet-
27 global investors managing $2.1 trillion collaborating to help companies reduce the potential negative impacts of tech on #mentalhealth of their customers; will engage with hardware, media, internet, gaming, software, edtech and telecom firms | @axaIM https://t.co/IKEkip1Kbb
-
Exclusive: Delays getting higher dose Wegovy to patients reported by US doctors https://t.co/TlQaBUHDJa